Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT04306237
Other study ID # CIMB-8972-201
Secondary ID
Status Suspended
Phase Phase 2
First received
Last updated
Start date November 2023
Est. completion date April 2025

Study information

Verified date April 2023
Source Imbria Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objectives of the study are to assess the safety, tolerability, and potential efficacy of IMB-1018972 on patients with refractory angina. Study will assess functional capacity employing a modified Bruce Protocol treadmill ETT, patient reports of angina symptoms via an electronic diary, and activity using an accelerometer.


Recruitment information / eligibility

Status Suspended
Enrollment 640
Est. completion date April 2025
Est. primary completion date February 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: 1. Is between the ages of 18 and 85 years, inclusive. 2. Is capable of understanding the written informed consent, and providing signed, dated, and witnessed written informed consent. 3. Has complied with and is willing to continue to comply with the specified procedures (eg, angina diary during screening) and complete specific follow-up evaluations. 4. Has coronary artery disease confirmed by at least one of the following: - Documented prior MI, CABG surgery, or PCI -OR- - Angiography performed within the 24 months prior to Visit 1 confirming CAD (eg, evidence of =70% stenosis of at least one major coronary artery or diffuse CAD). 5. Has evidence of stress induced ischemia documented by either: - Protocol-specified ETT ECG demonstrating at least 0.5 mm exercise-induced ST segment depression with onset <9 minutes on at least 1 of the screening ETTs -OR- - Prior evidence of stress-induced reversible perfusion defect in the last 24 months (without intervening revascularization) identified by at least one of the following: - Radionuclide imaging study - Echocardiographic imaging study - FFR <0.8 - IFR <0.89 - FFR CT <0.8 - CFR <2.5 6. Has a minimum 3 month history of exertional angina, including angina with a minimum frequency of 2 anginal episodes per week on average for the 2 weeks prior to enrolling in the study while on optimal guideline directed medical therapy for their angina. 7. Is on optimal, dual agent, antianginal therapy for their angina for at least 1 month prior to the first screening ETT. Consistent with ACC/AHA and ESC Class I guideline directed medical therapy (GDMT), criteria for optimal therapy include treatment with both: (a) a beta-adrenergic blocking agent and treatment with (b) a calcium channel blocker OR a long-acting nitrate. If unacceptable side effects are intolerable and documented with a therapy listed in (a) or (b), treatment with only 1 antianginal medication is acceptable. Additionally, patients should be treated with short-acting nitrates per GDMT. 8. Is currently not clinically indicated for coronary revascularization (ie, PCI or CABG) in the opinion of the principle investigator at the time of screening through 6 months after randomization. 9. Has a CCS score of II, III or stabilized IV for 1 month prior to screening. 10. Meets the following requirements after 2 screening modified Bruce protocol ETTs: a. Stopping the treadmill test due to angina on each test b. Total exercise duration must fall between 3 and 9 minutes on each test c. To document inducible myocardial ischemia: i. For those patients with interpretable ECGs, at least 0.5 mm exercise induced ST segment depression must occur with onset <9 minutes on at least 1 of the screening ETTs. d. Difference in TED between the 2 qualifying ETTs must not exceed 20% of the longer test or 1 minute, whichever limit is smaller. e. Consideration of a third ETT may be discussed by the investigator with the study medical monitor, who may authorize the performance of a third ETT a minimum of 5 days and no more than 10 days after the second ETT Exclusion Criteria: 1. If any of the following have occurred: - Use of TMZ anytime in prior history - In the prior 6 months: - Diagnosis of NYHA Class 3 or 4 (heart failure) - Hospitalization for heart failure - Coronary artery bypass graft surgery - Cardiac resynchronization therapy placement or adjustments to CRT parameters - Implantable cardioverter defibrillator or biventricular pacemaker placement - In the prior 3 months: - Hospitalization for a cardiovascular indication - Cerebral vascular accident - Transient ischemic attack - Percutaneous coronary intervention - In the prior 1 month: - Use of perhexiline or meldonium. 2. Has a history of moderate to severe valvular heart disease defined as aortic stenosis (valve area <1.5 cm2), aortic insufficiency, mitral stenosis (valve area <1.5 cm2), or mitral valve regurgitation of grade 3 or worse. 3. Has significant hepatic disease, with increased liver function tests such as total bilirubin, aspartate aminotransferase, or alanine aminotransferase more than 2 times of ULN at baseline (excluding patients with documented history of Gilbert syndrome). 4. Has severe renal impairment (ie, creatinine clearance <30 mL/min at screening, measured using 4-variable modification of diet in renal disease equation). 5. Has a history of Parkinson disease, Parkinsonian symptoms, tremors, restless leg syndrome, or other related movement disorders. 6. Has a history of vasospastic angina or microvascular angina. 7. Has an exacerbating cause for angina (eg, anemia [ie, hemoglobin <10 g/dL], uncontrolled hypertension [ie, BP =160/90 mmHg], hyperthyroid, or rapid AF [ie, AF with average rate >120 beats per minute]) at screening. 8. Has long-QT and life-threatening LV arrhythmia. 9. Has comorbidities limiting life expectancy to less than 3 years. 10. Is pregnant, planning pregnancy, or lactating. 11. Has a history of alcohol abuse or drug addiction. 12. Has a positive test for drugs (eg, opiates, methadone, cocaine, amphetamines [including ecstasy], or barbiturates) at screening. 13. Has a positive test for HBsAg, HCV antibodies, or HIV1/2 antibodies at screening. 14. Is participating in another research study. 15. Is an employee or family member of the investigator or study site personnel.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
IMB-1018972
IMB-1018972 200 mg tablet for oral administration
Placebo oral tablet
Matched placebo tablet for oral administration

Locations

Country Name City State
United States Imbria Investigational Site Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Imbria Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Modified Bruce Protocol Treadmill ETT Change from baseline to Week 8 in total exercise duration (seconds) 8 weeks
Primary Safety and Tolerability of IMB-1018972 in Patients with Refractory Angina Incidence of AEs, changes from baseline in physical examinations, vital signs, clinical laboratories, and ECG 16 weeks
Secondary Assess the benefit of IMB-1018972 on patient report of angina symptoms employing an electronic diary Change from baseline per week in the incidence of angina symptoms 16 weeks
Secondary Assess the potential treatment benefit of IMB-1018972 on patient report of rescue NTG use employing an electronic diary Change from baseline in daily counts of NTG use 16 weeks
Secondary Assess the potential treatment benefit of IMB-1018972 on patient activity employing a wearable device Change from baseline in total daily activity at Week 16 (activity units) 16 weeks
See also
  Status Clinical Trial Phase
Completed NCT01205893 - Coronary Sinus Reducer for Treatment of Refractory Angina - COSIRA Phase 2
Recruiting NCT04892537 - Coronary Sinus Reducer Objective Impact on Symptoms, MRI Ischaemia and Microvascular Resistance N/A
Completed NCT00694642 - Safety and Efficacy of Autologous Endothelial Progenitor Cell CD 133 for Therapeutic Angiogenesis Phase 1/Phase 2
Suspended NCT00820586 - Intramyocardial Delivery of Autologous Bone Marrow Phase 2
Recruiting NCT04368819 - Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms Phase 2/Phase 3
Recruiting NCT05711849 - Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina Phase 2
Recruiting NCT03455725 - CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial N/A
Completed NCT01966042 - Study Protocol of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina Phase 2
Recruiting NCT03991871 - HARapan kiTa ECP (External Counter Pulsation) Study HARTEC Study N/A
Recruiting NCT05102019 - Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II N/A
Completed NCT03218891 - Cardiac Rehabilitation in Patients With Refractory Angina N/A
Completed NCT01796912 - Lipoprotein Apheresis in Refractory Angina Study N/A
Completed NCT03350737 - Coronary Arteriogenetic Heparinized Exercise N/A
Recruiting NCT01566175 - Use of the Neovasc Coronary Sinus Reducer System for the Treatment of Refractory Angina Pectoris in Patients With Ngina Class 3-4 Who Are Not Candidates for Revascularization N/A
Recruiting NCT05492110 - Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction. N/A
Recruiting NCT04606459 - COSIMA: COronary SInus Reducer for the Treatment of Refractory Microvascular Angina N/A